On November 1, 2021 HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company reported that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for HFB200301 (Press release, HiFiBiO Therapeutics, NOV 1, 2021, View Source [SID1234594087]). HFB200301 is a first-in-class monoclonal agonist antibody designed to promote an antitumor response by stimulating both innate and adaptive immune systems through TNFR2 in solid tumors identified through HiFiBiO’s Drug Intelligent Science (DISTM) platform.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The FDA’s clearance of our IND for HFB200301 is an important milestone for HiFiBiO as it further demonstrates the power of our single cell-powered DIS platform to identify and develop novel therapeutics. This milestone also signifies our transition to a clinical stage company," said co-founder and CEO of HiFiBiO Therapeutics, Liang Schweizer, Ph.D. "The FDA’s clearance brings us one step closer toward achieving our mission of delivering novel therapeutics that improve treatment options for cancer patients"
"We were excited to discover that our TNFR2 clinical candidate not only stimulated effector CD4 and CD8 T cells, but also activated NK cells to drive anti-tumor activity" shared Francisco Adrián, Ph.D., CSO of HiFiBiO Therapeutics. "HFB200301 has shown strong in vivo efficacy alone and combined with anti-PD-1 at doses well tolerated in mice and NHPs."
"The planned Phase 1 clinical study will consist of an initial dose escalation followed by expansion cohorts in selected solid tumors identified through HiFiBiO DISTM platform. The company is also exploring a potential combination with checkpoint inhibitor therapy", said Luigi Manenti, M.D., CMO of HiFiBiO Therapeutics. "We remain committed to further developing novel immune therapies for patients with cancer and autoimmune diseases."
HFB2003 (TNFR2)
HFB200301 is a first-in-class agonistic anti-TNFR2 antibody that binds potently and selectively to TNFR2 and induces the activation of CD4 T cells, CD8 T cells and NK cells. In vivo, HFB200301 demonstrates potent antitumor activity as a single agent and in combination with anti-PD-1. HiFiBiO is applying a biomarker strategy by leveraging its DIS platform to select patients who may benefit the most from HFB200301 treatment.